thiazoles has been researched along with Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted in 48 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (31.25) | 29.6817 |
| 2010's | 32 (66.67) | 24.3611 |
| 2020's | 1 (2.08) | 2.80 |
| Authors | Studies |
|---|---|
| Kuter, DJ | 1 |
| Abe, S; Kamimura, K; Kawai, H; Sakamaki, A; Takamura, M; Terai, S; Tsuchiya, A; Watanabe, T; Yamagiwa, S | 1 |
| Lee, JM; Park, JH; Yang, CM; Yoon, JC | 1 |
| Abdel-Hakeem, MS; Houghton, M; Mason, AL; Sarhan, MA; Tyrrell, DL | 1 |
| Huang, F; Rowland, L; Sabo, JP; Schultz, A; Trampisch, M; Voelk, C | 1 |
| Kikelj, D; Lillsunde, KE; Lohmann, V; Schult, P; Tammela, P; Tomašič, T | 1 |
| Chao, YS; Chen, CT; Chern, JH; Hsu, SJ; Hsu, TA; Kang, IJ; Lee, CC; Lee, YC; Tian, YW; Yang, HY; Yeh, TK; Yueh, A | 1 |
| Bichoupan, K; Dieterich, DT; Martel-Laferrière, V | 1 |
| Boccaccio, V; Bruno, S | 1 |
| Dieterich, DT; Martel-Laferrière, V | 1 |
| Asselah, T; Marcellin, P | 1 |
| Asselah, T; Halfon, P; Marcellin, P; Schinazi, R | 1 |
| Ford, N; Fortunak, J; Hill, A; Khoo, S; Simmons, B | 1 |
| Asselah, T; Berg, T; Böcher, WO; Datsenko, Y; Dieterich, D; Ferenci, P; Guyader, D; Larrey, D; Maieron, A; Mauss, S; Ozan, M; Ratziu, V; Schuchmann, M; Steinmann, G; Stern, JO | 1 |
| Ballow, C; Battegay, M; Elgadi, M; Feifel, U; Fuhr, R; Girlich, B; Haschke, M; Kort, J; Lang, B; Li, Y; Sabo, JP; Schobelock, M | 1 |
| Asselah, T; Böcher, WO; Huang, Q; Li, Y; Mease, K; Nehmiz, G; Olson, S; Podila, L; Sane, RS; Steinmann, GG; Stern, JO; Taub, ME; Tweedie, D | 1 |
| Elgadi, M; Halabi, A; Huang, F; Lang, B; Moschetti, V; Petersen-Sylla, M; Yong, CL | 1 |
| Ballow, C; Battegay, M; Chan, TS; Cooper, C; Girlich, B; Haschke, M; Kashuba, AD; Kort, J; Lang, B; Li, Y; O'Brien, D; Sabo, JP; Seibert, E; Ting, N; Tweedie, D; Zhang, W | 1 |
| Agarwal, K; Barnabas, A | 1 |
| Gao, C; Lei, Q; Liu, L; Liu, ZH; Peng, CT; Song, XJ; Tang, H; Wang, NY; Wei, YQ; Xia, Y; Xiao, KJ; Xiong, Y; Xu, Y; Yang, SY; Ye, TH; You, XY; Yu, LT; Zeng, XX; Zhang, LD; Zuo, WQ | 1 |
| Kanda, T; Omata, M; Yokosuka, O | 1 |
| Barouch-Bentov, R; Bekerman, E; Chaikuad, A; Chang, L; De Jonghe, S; Einav, S; Herdewijn, P; Heroven, C; Knapp, S; Kovackova, S; Neveu, G; Šála, M | 1 |
| Campagna, D; Demma, S | 1 |
| Gani, R; Lee, S; Price, P; Saraswati, H; Tan, D; Yunihastuti, E | 1 |
| Khan, H; Murad, S; Neyts, J; Paeshuyse, J | 1 |
| Asselah, T; Baum, P; Böcher, WO; Bourlière, M; Bronowicki, JP; Buti, M; Gallivan, JP; Gane, EJ; Lohse, AW; Mensa, FJ; Müllhaupt, B; Roberts, SK; Schuchmann, M; Soriano, V; Stern, JO; Voss, F; Zeuzem, S | 1 |
| Gonzàlez-Candelas, F; López-Labrador, FX; Moya, A | 1 |
| Allen, TM; Berical, A; Berlin, AM; Bihl, F; Birch, C; Birren, BW; Carlson, J; Cerny, A; Chung, RT; Daar, ES; Donfield, SM; Edlin, BR; Fleckenstein, JF; Galagan, JE; Gomperts, ED; Heckerman, D; Henn, MR; Jacobson, IM; Kim, AY; Kleyman, M; Kodira, C; Koehrsen, M; Kuntzen, T; Lake-Bakaar, GV; Lauer, GM; Ledlie, T; Lee, B; Lennon, N; Liu, Z; Madey, MA; Marion, T; McMahon, CM; Nusbaum, C; Park, VM; Reyor, LL; Roberts, AD; Rosen, HR; Schneidewind, A; Schulze Zur Wiesch, J; Spengler, U; Talal, AH; Timm, J; Walker, BD; Xing, Y; Young, SK | 1 |
| Elazar, M; Gehrig, EA; Glenn, JS; Liu, M; Liu, P; McKenna, SA; Puglisi, JD; Rossignol, JF | 1 |
| de Ruiter, P; Janssen, HL; Kwekkeboom, J; Metselaar, HJ; Pan, Q; Tilanus, HW; van der Laan, LJ | 1 |
| Deshpande, M; Huang, M; Miller, MD; Mo, H; Murray, B; Qi, X; Rhodes, G; Sun, SC; Wang, K; Wang, Y; Yang, C | 1 |
| Benhamou, Y; Berg, T; Boecher, WO; Bonacini, M; Bourlière, M; Calleja, JL; Kukolj, G; Manns, MP; Pol, S; Scherer, J; Steinmann, G; Stern, JO; Trepo, C; White, PW; Wright, D; Yong, CL | 1 |
| Goudreau, N; Hucke, O; Lemke, CT; Llinàs-Brunet, M; Thibeault, D; White, PW; Zhao, S | 1 |
| Korba, B; Rossignol, JF; Viswanathan, P; Yon, C | 1 |
| Ciesek, S; Manns, MP; von Hahn, T | 1 |
| Alvarez, C; Ananthan, S; Arasappan, A; Bansal, N; Bennett, F; Chase, R; Chen, L; Clark, JL; Curry, S; Fowler, AT; Gavalas, S; Girijavallabhan, VM; Huang, HC; Huang, Y; Kezar, HS; Kim, SH; Kosinski, A; Kozlowski, J; Kwong, CD; Li, C; MacCoss, M; Maddry, JA; Njoroge, FG; Pinto, P; Piwinski, JJ; Reynolds, RC; Rizvi, R; Rossman, R; Secrist, JA; Shankar, B; Shih, NY; Tong, L; Tong, X; Valiyaveettil, J; Velazquez, F; Venkatraman, S; Verma, VA | 1 |
| Chow, WH; Davies, C; Jiang, J; Li, GW; Pan, CY; Shi, HL; Sun, XC; Tian, H; Yang, WY; Zhu, XX | 1 |
| Rice, CM | 1 |
| Anderson, PC; Bailey, M; Beaulieu, P; Bolger, G; Bonneau, P; Bös, M; Cameron, DR; Cartier, M; Cordingley, MG; Faucher, AM; Goudreau, N; Kawai, SH; Kukolj, G; Lagacé, L; Lamarre, D; LaPlante, SR; Llinàs-Brunet, M; Narjes, H; Poupart, MA; Rancourt, J; Sentjens, RE; Simoneau, B; St George, R; Steinmann, G; Thibeault, D; Tsantrizos, YS; Weldon, SM; Yong, CL | 1 |
| Wei, L | 1 |
| Tsantrizos, YS | 1 |
| Pawlotsky, JM | 1 |
| Anzola, J; Lee, G; Li, Y; Piper, DE; Powers, J; Walker, N; Wang, Z | 1 |
| Aukerman, L; Collett, M; Douglas, D; Gao, T; Hashash, A; Hsi, B; Kline, J; Kneteman, NM; Kovelsky, R; Mercer, DF; Ni, ZJ; O'Connell, J; Schiller, D; Tyrrell, DL; Weiner, AJ; Zhu, Q | 1 |
| Aukerman, SL; Garrett, EN; Hollenbach, PW; Mendel, DB; Oei, Y; Patawaran, MB; Weiner, AJ; Zhu, Q | 1 |
| De Vos, R; Leroux-Roels, G; Libbrecht, L; Meuleman, P; Roskams, T; Vanwolleghem, T | 1 |
| Cheng, G; Chisari, FV; Fredericksen, B; Gallay, PA; Gastaminza, P; Ghadiri, MR; Isogawa, M; Montero, A; Selvarajah, S; Whitten-Bauer, C; Wieland, SF | 1 |
10 review(s) available for thiazoles and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
| Article | Year |
|---|---|
The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag.
Topics: Anemia, Aplastic; Hepatitis C; Humans; Liver Diseases; Receptors, Thrombopoietin; Thiazoles; Thiophenes; Thrombopoietin | 2022 |
Hepatitis C direct-acting antiviral agents: changing the paradigm of hepatitis C treatment in HIV-infected patients.
Topics: Aminoisobutyric Acids; Antiviral Agents; Coinfection; Hepatitis C; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Interferons; Leucine; Oligopeptides; Proline; Protease Inhibitors; Quinolines; Simeprevir; Sulfonamides; Thiazoles; Viral Nonstructural Proteins | 2014 |
Management of HCV patients with cirrhosis with direct acting antivirals.
Topics: Algorithms; Aminoisobutyric Acids; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Leucine; Liver Cirrhosis; Oligopeptides; Proline; Quinolines; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Time Factors; Uridine Monophosphate | 2014 |
Treating HCV in HIV 2013: on the cusp of change.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Leucine; Oligopeptides; Proline; Pyrrolidines; Quinolines; Sofosbuvir; Thiazoles; Treatment Outcome; Uridine Monophosphate; Valine | 2014 |
Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir.
Topics: Aminoisobutyric Acids; Antiviral Agents; Clinical Trials as Topic; Drug Approval; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Leucine; Oligopeptides; Proline; Quinolines; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Time Factors; Uridine Monophosphate | 2014 |
HCV direct-acting antiviral agents: the best interferon-free combinations.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials as Topic; Disease Eradication; Drug Discovery; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Leucine; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Pyrrolidines; Quinolines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate; Valine; Viral Nonstructural Proteins; Virus Replication | 2014 |
Faldaprevir for the treatment of genotype-1 hepatitis C virus.
Topics: Aminoisobutyric Acids; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Leucine; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Quinolines; Ribavirin; Thiazoles | 2015 |
Faldaprevir for the treatment of hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Leucine; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Thiazoles; Viral Nonstructural Proteins | 2015 |
Faldaprevir for the treatment of hepatitis C.
Topics: Aminoisobutyric Acids; Animals; Antiviral Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Discovery; Drug Interactions; Hepatitis C; Humans; Leucine; Molecular Structure; Oligopeptides; Proline; Quinolines; Thiazoles; Tissue Distribution; Treatment Outcome; Viral Nonstructural Proteins | 2015 |
Second-wave protease inhibitors: choosing an heir.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carrier Proteins; Cyclopropanes; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Intracellular Signaling Peptides and Proteins; Isoindoles; Lactams; Lactams, Macrocyclic; Leucine; Oligopeptides; Proline; Protease Inhibitors; Quinolines; Simeprevir; Sulfonamides; Thiazoles; Viral Nonstructural Proteins | 2011 |
10 trial(s) available for thiazoles and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
| Article | Year |
|---|---|
Pharmacokinetic Interaction between Faldaprevir and Cyclosporine or Tacrolimus in Healthy Volunteers: A Prospective, Open-Label, Fixed-Sequence, Crossover Study.
Topics: Adolescent; Adult; Aminoisobutyric Acids; Antiviral Agents; Area Under Curve; Cross-Over Studies; Cyclosporine; Drug Interactions; Female; Graft Rejection; Healthy Volunteers; Hepatitis C; Humans; Immunosuppressive Agents; Leucine; Liver Transplantation; Male; Middle Aged; Oligopeptides; Proline; Prospective Studies; Quinolines; Secondary Prevention; Tacrolimus; Thiazoles; Young Adult | 2018 |
SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients.
Topics: Adolescent; Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Carrier Proteins; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Leucine; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; RNA, Viral; Thiazoles; Viral Nonstructural Proteins; Young Adult | 2014 |
Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
Topics: Adenine; Adult; Alkynes; Aminoisobutyric Acids; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Coinfection; Cyclopropanes; Darunavir; Drug Interactions; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Leucine; Male; Middle Aged; Oligopeptides; Organophosphonates; Proline; Protease Inhibitors; Quinolines; Ritonavir; Sulfonamides; Tenofovir; Thiazoles; Young Adult | 2014 |
Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients.
Topics: Aminoisobutyric Acids; Animals; Bilirubin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Double-Blind Method; Glucuronosyltransferase; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Hyperbilirubinemia; Leucine; Liver; Macaca mulatta; Multicenter Studies as Topic; Multidrug Resistance-Associated Protein 2; Oligopeptides; Proline; Quinolines; Randomized Controlled Trials as Topic; Rats; Thiazoles | 2014 |
Pharmacokinetics, safety, and tolerability of faldaprevir in patients with renal impairment.
Topics: Adult; Aged; Aminoisobutyric Acids; Biological Availability; Female; Half-Life; Hepatitis C; Humans; Leucine; Male; Middle Aged; Oligopeptides; Proline; Quinolines; Renal Insufficiency; Thiazoles | 2015 |
Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: in vitro and in vivo correlation.
Topics: Adolescent; Adult; Aminoisobutyric Acids; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Female; Healthy Volunteers; Hepatitis C; Humans; In Vitro Techniques; Isoenzymes; Leucine; Male; Microsomes, Liver; Midazolam; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Quinolines; Thiazoles; Warfarin; Young Adult | 2015 |
ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection.
Topics: Acrylates; Aminoisobutyric Acids; Anemia; Antiviral Agents; Benzimidazoles; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Leucine; Male; Middle Aged; Oligopeptides; Polymorphism, Single Nucleotide; Proline; Pyrophosphatases; Quinolines; Real-Time Polymerase Chain Reaction; Ribavirin; Thiazoles | 2015 |
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carrier Proteins; Double-Blind Method; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Leucine; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Viral Load; Viral Nonstructural Proteins | 2011 |
Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C.
Topics: Adult; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Environmental Exposure; Female; Gliclazide; Glyburide; Glycated Hemoglobin; Hepatitis B; Hepatitis C; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2003 |
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
Topics: Administration, Oral; Antiviral Agents; Carbamates; Double-Blind Method; Hepacivirus; Hepatitis C; Humans; Macrocyclic Compounds; Male; Polyproteins; Protein Processing, Post-Translational; Quinolines; Serine Proteinase Inhibitors; Thiazoles; Viral Load; Viral Nonstructural Proteins; Viral Proteins | 2003 |
28 other study(ies) available for thiazoles and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
| Article | Year |
|---|---|
Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient.
Topics: Carcinoma, Hepatocellular; Cinnamates; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Thiazoles; Thrombocytopenia | 2017 |
Hepatitis C virus impairs natural killer cell activity via viral serine protease NS3.
Topics: Carbamates; Cell Line; Cell Survival; Coculture Techniques; Down-Regulation; Hepacivirus; Hepatitis C; Humans; Interferon-gamma; Interleukin-12; K562 Cells; Killer Cells, Natural; Macrocyclic Compounds; Microscopy, Confocal; Natural Cytotoxicity Triggering Receptor 1; Natural Cytotoxicity Triggering Receptor 3; Quinolines; Recombinant Proteins; Serine Proteinase Inhibitors; Thiazoles; Viral Nonstructural Proteins | 2017 |
Glycogen synthase kinase 3β inhibitors prevent hepatitis C virus release/assembly through perturbation of lipid metabolism.
Topics: Apolipoproteins B; Apolipoproteins E; Cell Line; Glycogen Synthase Kinase 3 beta; Hepacivirus; Hepatitis C; Humans; Lipid Metabolism; Lithium Chloride; Thiazoles; Urea; Virion; Virus Replication | 2017 |
Inhibition of Hepatitis C Replication by Targeting the Molecular Chaperone Hsp90: Synthesis and Biological Evaluation of 4,5,6,7-Tetrahydrobenzo[1,2-d]thiazole Derivatives.
Topics: Antiviral Agents; Benzothiazoles; Dose-Response Relationship, Drug; Drug Design; Hepacivirus; Hepatitis C; HSP90 Heat-Shock Proteins; Humans; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Thiazoles; Virus Replication | 2019 |
A novel, potent, and orally bioavailable thiazole HCV NS5A inhibitor for the treatment of hepatitis C virus.
Topics: Amides; Animals; Biological Availability; Dogs; Drug Discovery; Hepacivirus; Hepatitis C; Humans; Rats; Sialyltransferases; Structure-Activity Relationship; Thiazoles; Viral Nonstructural Proteins | 2019 |
Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.
Topics: Aminoisobutyric Acids; Anti-HIV Agents; Antiviral Agents; Carbamates; Developing Countries; Drug Industry; Drug Therapy, Combination; Health Services Accessibility; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Leucine; Oligopeptides; Proline; Pyrrolidines; Quinolines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate; Valine | 2014 |
Discovery of imidazo[2,1-b]thiazole HCV NS4B inhibitors exhibiting synergistic effect with other direct-acting antiviral agents.
Topics: Antiviral Agents; Cell Line; Drug Synergism; Genotype; Hepacivirus; Hepatitis C; Humans; Mutation; Thiazoles; Viral Nonstructural Proteins | 2015 |
Selective Inhibitors of Cyclin G Associated Kinase (GAK) as Anti-Hepatitis C Agents.
Topics: Antiviral Agents; Cell Line; Crystallography, X-Ray; Hepacivirus; Hepatitis C; Humans; Intracellular Signaling Peptides and Proteins; Models, Molecular; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Thiazoles; Virus Internalization | 2015 |
Increased proportions of dendritic cells and recovery of IFNγ responses in HIV/HCV co-infected patients receiving ART.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Arthritis, Infectious; Cells, Cultured; Coinfection; Cytokines; Dendritic Cells; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Indonesia; Male; Middle Aged; Quinolines; Thiazoles; Young Adult | 2016 |
Assessment of the activity of directly acting antivirals and other products against different genotypes of hepatitis C virus prevalent in resource-poor countries.
Topics: Antiviral Agents; Catechin; Food Additives; Genotype; Hepacivirus; Hepatitis C; Humans; Nitro Compounds; Prevalence; Silybin; Silymarin; Thiazoles; Virus Replication | 2016 |
Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
Topics: Amino Acid Sequence; Antiviral Agents; Carbamates; Carrier Proteins; Drug Resistance, Viral; Global Health; Hepacivirus; Hepatitis C; Humans; Intracellular Signaling Peptides and Proteins; Macrocyclic Compounds; Microbial Sensitivity Tests; Molecular Sequence Data; Oligopeptides; Polymorphism, Genetic; Proline; Protease Inhibitors; Quinolines; Sequence Alignment; Thiazoles; Viral Nonstructural Proteins; Viral Proteins | 2008 |
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.
Topics: Antiviral Agents; Carbamates; Cohort Studies; Drug Resistance, Viral; Female; Genetic Testing; Hepacivirus; Hepatitis C; Humans; Macrocyclic Compounds; Male; Mutation; Oligopeptides; Phenylthiourea; Phylogeny; Proline; Protease Inhibitors; Quinolines; Thiazoles; Viral Load; Viral Nonstructural Proteins | 2008 |
The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation.
Topics: Antiparasitic Agents; Antiviral Agents; Cell Culture Techniques; Cell Line; eIF-2 Kinase; Eukaryotic Initiation Factor-2; Hepatitis C; Hepatocytes; Humans; Interferons; Nitro Compounds; Phosphorylation; Thiazoles | 2009 |
Calcineurin inhibitor tacrolimus does not interfere with the suppression of hepatitis C virus infection by interferon-alpha.
Topics: Antiviral Agents; Calcineurin Inhibitors; Cell Proliferation; Cell Survival; Gene Expression Regulation; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon-alpha; T-Lymphocytes; Tacrolimus; Tetrazolium Salts; Thiazoles | 2010 |
Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors.
Topics: Antiviral Agents; Blood Proteins; Carbamates; Cell Line; Comparative Effectiveness Research; Dialysis; Hepacivirus; Hepatitis C; Humans; Inhibitory Concentration 50; Macrocyclic Compounds; Membranes, Artificial; Oligopeptides; Phenylthiourea; Plasma; Proline; Protease Inhibitors; Protein Binding; Quinolines; RNA, Viral; Thiazoles; Viral Load | 2011 |
Combined X-ray, NMR, and kinetic analyses reveal uncommon binding characteristics of the hepatitis C virus NS3-NS4A protease inhibitor BI 201335.
Topics: Aminoisobutyric Acids; Carrier Proteins; Catalytic Domain; Clinical Trials, Phase I as Topic; Crystallography, X-Ray; Hepacivirus; Hepatitis C; Humans; Intracellular Signaling Peptides and Proteins; Leucine; Nuclear Magnetic Resonance, Biomolecular; Oligopeptides; Proline; Protease Inhibitors; Protein Binding; Quinolines; Thiazoles; Viral Nonstructural Proteins | 2011 |
Mutations in HCV non-structural genes do not contribute to resistance to nitazoxanide in replicon-containing cells.
Topics: Antiviral Agents; Base Sequence; Cell Line; Cloning, Molecular; Drug Resistance, Viral; Escherichia coli; Genotype; Hepacivirus; Hepatitis C; Host-Pathogen Interactions; Humans; Interferons; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; Nitro Compounds; Phenotype; Plasmids; Replicon; RNA, Viral; Thiazoles; Transformation, Bacterial; Viral Nonstructural Proteins; Virus Replication | 2011 |
Synthesis and SAR of pyridothiazole substituted pyrimidine derived HCV replication inhibitors.
Topics: Animals; Antiviral Agents; Dogs; Hepacivirus; Hepatitis C; Humans; Pyrimidines; Rats; Structure-Activity Relationship; Thiazoles; Virus Replication | 2012 |
Virology: fresh assault on hepatitis C.
Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Design; Hepacivirus; Hepatitis C; Humans; Macrocyclic Compounds; Quinolines; Serine Proteinase Inhibitors; Thiazoles; Viral Load; Viral Nonstructural Proteins | 2003 |
[Review of recent research on hepatitis C therapy for 54th annual meeting of the American association for the study of liver diseases].
Topics: Carbamates; Hepatitis C; Humans; Interferon-alpha; Interferons; Macrocyclic Compounds; Oligonucleotides, Antisense; Quinolines; RNA-Dependent RNA Polymerase; Serum Albumin; Serum Albumin, Human; Thiazoles; Viral Hepatitis Vaccines | 2004 |
Hepatitis C drug being developed.
Topics: Carbamates; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Macrocyclic Compounds; Quinolines; Thiazoles; Treatment Outcome; Viral Load | 2004 |
The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
Topics: Carbamates; Drug Design; Hepacivirus; Hepatitis C; Humans; In Vitro Techniques; Macrocyclic Compounds; Models, Molecular; Nuclear Magnetic Resonance, Biomolecular; Quinolines; Serine Proteinase Inhibitors; Static Electricity; Thiazoles; Viral Nonstructural Proteins | 2004 |
Hepatitis C: it's a long way to new therapy, it's a long way to go...
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Macrocyclic Compounds; Quinolines; Thiazoles | 2004 |
Novel inhibitors of hepatitis C virus RNA-dependent RNA polymerases.
Topics: Hepacivirus; Hepatitis C; Humans; Models, Molecular; Molecular Structure; Protein Structure, Tertiary; RNA-Dependent RNA Polymerase; Thiazoles; Viral Nonstructural Proteins | 2006 |
Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application.
Topics: Analysis of Variance; Animals; Antiviral Agents; Base Sequence; Carbamates; Disease Models, Animal; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Interferon alpha-2; Interferon-alpha; Macrocyclic Compounds; Mice; Mice, SCID; Molecular Sequence Data; Oncogene Proteins, Fusion; Probability; Quinolines; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Sensitivity and Specificity; Thiazoles; Treatment Outcome | 2006 |
Novel robust hepatitis C virus mouse efficacy model.
Topics: Animals; Antiviral Agents; Carbamates; Cell Line, Tumor; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Macrocyclic Compounds; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Quinolines; Thiazoles; Virus Replication | 2006 |
Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse.
Topics: Administration, Oral; Animals; Antiviral Agents; Carbamates; Drug Evaluation, Preclinical; Heart Diseases; Hepacivirus; Hepatitis C; Humans; Liver; Liver Transplantation; Macrocyclic Compounds; Mice; Mice, SCID; Mice, Transgenic; Mitochondria, Heart; Mitochondrial Swelling; Models, Animal; Myocytes, Cardiac; Protease Inhibitors; Quinolines; Thiazoles; Time Factors; Transplantation, Heterologous; Urokinase-Type Plasminogen Activator; Viral Load; Viral Nonstructural Proteins | 2007 |
A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.
Topics: Amino Acid Sequence; Antiviral Agents; Cell Line; Circular Dichroism; Cytotoxicity Tests, Immunologic; Hepacivirus; Hepatitis C; Humans; In Vitro Techniques; Molecular Sequence Data; Peptides; Reverse Transcriptase Polymerase Chain Reaction; Structure-Activity Relationship; Tetrazolium Salts; Thiazoles; Virus Replication | 2008 |